VA Boston Healthcare System, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
ESC Heart Fail. 2023 Jun;10(3):1555-1569. doi: 10.1002/ehf2.14248. Epub 2022 Dec 9.
In patients with heart failure with preserved ejection fraction (HFpEF), sudden cardiac death (SCD) accounts for approximately 25-30% of all-cause mortality and 40% of cardiovascular mortality in properly adjudicated large clinical trials. The mechanism of SCD in HFpEF remains unknown but thought to be driven by arrhythmic events. Apart from atrial fibrillation, which is prevalent in approximately 45% of HFpEF patients, the true burden of other cardiac arrhythmias in HFpEF remains undetermined. The incidence and risk of clinically significant advanced cardiac conduction disease with bradyarrhythmias and ventricular arrhythmias remain less known. Recommendations have been made for long-term cardiac rhythm monitoring to determine the incidence of arrhythmias and clarify mechanisms and mode of death in HFpEF patients. In animal studies, spontaneous ventricular arrhythmias and SCD are significantly elevated in HFpEF animals compared with controls without heart failure. In humans, these studies are scant, with a few published small-size studies suggesting an increased incidence of ventricular arrhythmias in HFpEF. Higher rates of clinically significant conduction disease and cardiac pacing are seen in HFpEF compared with the general population. Excepting atrial fibrillation, the predictive effect of other arrhythmias on heart failure hospitalization, all-cause mortality, and precisely SCD remains unknown. Given the high occurrence of SCD in the HFpEF population, it could potentially become a target for therapeutic interventions if driven by arrhythmias. Studies to address these knowledge gaps are urgently warranted. In this review, we have summarized data on arrhythmias and SCD in HFpEF while highlighting avenues for future research in this area.
在射血分数保留的心力衰竭(HFpEF)患者中,心源性猝死(SCD)约占所有原因死亡率的 25-30%,也是经过适当裁决的大型临床试验中心血管死亡率的 40%。HFpEF 患者 SCD 的发生机制尚不清楚,但认为是由心律失常事件引起的。除了在大约 45%的 HFpEF 患者中普遍存在的心房颤动外,HFpEF 中其他心律失常的真实负担仍未确定。临床上有意义的心律失常的发生率以及缓慢性心律失常和室性心律失常的风险仍然知之甚少。已经提出了长期心脏节律监测的建议,以确定心律失常的发生率,并阐明 HFpEF 患者的死亡机制和方式。在动物研究中,HFpEF 动物自发性室性心律失常和 SCD 的发生率明显高于无心力衰竭的对照组。在人类中,这些研究很少,少数已发表的小规模研究表明 HFpEF 患者室性心律失常的发生率增加。HFpEF 患者的传导疾病和心脏起搏的发生率明显高于一般人群。除了心房颤动外,其他心律失常对心力衰竭住院、全因死亡率以及确切的 SCD 的预测作用仍不清楚。鉴于 HFpEF 人群中 SCD 的高发生率,如果由心律失常引起,它可能成为治疗干预的目标。迫切需要开展研究来解决这些知识空白。在这篇综述中,我们总结了 HFpEF 中心律失常和 SCD 的相关数据,同时强调了该领域未来研究的方向。